Cognition Therapeutics, Inc. · NASDAQ:CGTX
Cognition Therapeutics — Jefferies Global Healthcare Conference 2026
17 slides from Cognition Therapeutics's conference presentation, Jun 4, 2026
Slide 1: An Investigational Oral Therapy Advancing Toward Registrational Development
https://cogrx.com COGNITION THERAPEUTICS · NASDAQ: CGTX An Investigational Oral Therapy Advancing Toward Registrational Development June 2026 · Jefferies Global Healthcare Conference Zervimesine in DLB Psychosis
Slide 2: Forward-Looking Statements
2 COGNITION THERAPEUTICS | NASDAQ: CGTX FORWARD - LOOKING STATEMENTS This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements contained in this presentation, other than statements of historical facts or statem
Slide 3: Cognition Therapeutics Fundamentals
3 COGNITION THERAPEUTICS | NASDAQ: CGTX Cognition Therapeutics Fundamentals Clinical - stage CNS drug developer — one lead asset, two strategic indications Corporate Profile CGTX / NASDAQ Ticker / Exchange Purchase, NY Headquarters Clinical - stage (Phase 3 - registrational trial planned) Stage Zerv
Slide 4: Investment Highlights
4 COGNITION THERAPEUTICS | NASDAQ: CGTX Investment Highlights Five pillars shaping the Cognition Therapeutics investment case today No approved medications specifically for DLB psychosis. Patients have limited options. Unmet Need SHIMMER Phase 2: • Benefit across symptom domains: neuropsych , cognit
Slide 5: Understanding DLB Psychosis
5 COGNITION THERAPEUTICS | NASDAQ: CGTX Understanding DLB Psychosis A progressive and under - recognized disease with no approved treatments What is Dementia with Lewy Bodies (DLB)? • 2nd most common cause of dementia after Alzheimer's • Affects behavior, thinking, movement, and sleep — often simult
Slide 6: Why DLB Psychosis Matters
6 COGNITION THERAPEUTICS | NASDAQ: CGTX Why DLB Psychosis Matters A high - burden, high - prevalence symptom cluster with no approved treatment options ~80% of DLB patients experience psychosis (hallucinations and/or delusions) (1) ZERO FDA - approved drugs specifically for DLB psychosis today #1 ps
Slide 7: Key Limitation in DLB Off-label Options
7 COGNITION THERAPEUTICS | NASDAQ: CGTX Key Limitation in DLB Off - label Options Symptom Domain Atypicals can trigger severe, potentially fatal motor reactions (neuroleptic sensitivity) • Traditional antipsychotics (haloperidol); • Atypical antipsychotics (pimavanserin, brexpiprazole ); • Muscari
Slide 8: Key Limitation in DLB: Current Landscape for Neuropsychiatric Symptoms
8 COGNITION THERAPEUTICS | NASDAQ: CGTX Key Limitation in DLB How Used Approach Can trigger severe motor reactions (neuroleptic sensitivity) — potentially fatal in Lewy body patients Off - label, commonly tried Traditional Antipsychotics (e.g. haloperidol) Increased mortality in elderly with psychos
Slide 9: Zervimesine (CT1812) — Product Profile
9 COGNITION THERAPEUTICS | NASDAQ: CGTX Zervimesine (CT1812) — Product Profile An oral small molecule with a practical profile for a population that needs it most • Generally well tolerated in >450 patients • No ARIA expectation from MoA • AE rates comparable to placebo in 100mg dose group Safety Pr
Slide 10: How Zervimesine is Designed to Work
10 COGNITION THERAPEUTICS | NASDAQ: CGTX How Zervimesine is Designed to Work Targeting the biology of DLB — treating the underlying disease Toxic proteins Accumulate in DLB brain 1 Neuron signals are blocked synaptic breakdown Psychosis & symptoms emerge hallucinations, delusions Zervimesine acts on
Slide 11: SHIMMER: Phase 2 Study Design
11 COGNITION THERAPEUTICS | NASDAQ: CGTX SHIMMER: Phase 2 Study Design A grant - funded Phase 2 study designed to detect efficacy across DLB symptom domains • Age 50 - 85 • DLB diagnosis • MMSE 18 - 27 • MRI screening • 130 participants • 31 U.S. sites • Funded by $30M NIA grant Enrollment • Safety
Slide 12: SHIMMER Phase 2: Key Findings
12 COGNITION THERAPEUTICS | NASDAQ: CGTX SHIMMER Phase 2: Key Findings The strongest effects were seen in neuropsychiatric symptoms Strong Early Data Supporting CT1812 for DLB 1. Galvin et al. Phase 2 study of zervimesine (CT1812) in participants with mild - to - moderate dementia with Lewy bodies (
Slide 13: From Phase 2 Results to Registrational Program
13 COGNITION THERAPEUTICS | NASDAQ: CGTX From Phase 2 Results to Registrational Program Plans for the next study design — and why the path is credible Registrational Study in Development (Next Step) DLB psychosis (hallucinations, delusions) Indication Overseen by FDA Division of Psychiatry (meeting
Slide 14: Regulatory Progress and Next Steps
14 COGNITION THERAPEUTICS | NASDAQ: CGTX Regulatory Progress and Next Steps Structured FDA dialogue has been ongoing — the company has completed key preparatory meetings DLB Expanded Access Program Opens Patients and families driven to maintain access. Program filled to capacity immediately — signal
Slide 15: Clinical Studies in Alzheimer's Disease
15 COGNITION THERAPEUTICS | NASDAQ: CGTX Clinical Studies in Alzheimer’s Disease Strong results in mild - to - moderate Alzheimer’s disease in SHINE study – strongest in low p - tau217 • Age 50 - 85 • AD confirmed with PET or biomarker • MMSE 18 - 26 • MRI screening • 153 participants • 32 int’l sit
Slide 16: START Trial: MCI through Mild Alzheimer's Disease
16 COGNITION THERAPEUTICS | NASDAQ: CGTX • Appx 15% of participants are on stable background of immunotherapeutics • Data expected 2027 • Expands clinical insight from mild - to - moderate Alzheimer’s (SHINE trial) to larger Alzheimer’s spectrum: MCI through moderate disease START Trial: MCI through
Slide 17: Highly Experienced Management Team Coupled with External Support
17 COGNITION THERAPEUTICS | NASDAQ: CGTX Highly Experienced Management Team Coupled with External Support and Third - Party Validation A team with CNS experience, backed by NIH, analyst consensus, and patient demand NIH/NIA Grant Funding >$170M in non - dilutive grants. $25.6M obligated NIA grant fu
Cognition Therapeutics — Jefferies Global Healthcare Conference 2026 on 6ix